コンテンツへスキップ
Merck

HMHEMAG-34K

Millipore

MILLIPLEX® Human Metabolic Hormone Magnetic Bead Panel - Metabolism Multiplex Assay

The Human Metabolic Hormone Panel, using the Luminex xMAP technology, enables the simultaneous analysis of 13 protein biomarkers in human serum, plasma and cell/tissue culture samples.

別名:

human metabolic hormone immunoassay panel, luminex human metabolic hormone multiplex assay, millipore human metabolism multiplex kit

ログイン組織・契約価格を表示する


About This Item

UNSPSCコード:
12161503
eCl@ss:
32161000

To order a Milliplex® kit, please search for your analyte of interest.

交差性

human

メーカー/製品名

Milliplex®

assay range

accuracy: 101%
(Glucagon)

accuracy: 102%
(Leptin)

accuracy: 103%
(GIP)

accuracy: 103%
(GLP-1 (Total))

accuracy: 105%
(Ghrelin (Active))

accuracy: 106%
(MCP-1)

accuracy: 97%
(TNFα)

accuracy: 99%
(C-Peptide)

sensitivity: 0.5 pg/mL
(MinDC+2SD; TNF?)

sensitivity: 1.1 pg/mL
(MinDC+2SD; GIP)

sensitivity: 13 pg/mL
(MinDC+2SD; IL-6)

sensitivity: 14 pg/mL
(MinDC+2SD; Ghrelin (Active))

sensitivity: 14 pg/mL
(MinDC+2SD; MCP-1)

sensitivity: 146 pg/mL
(MinDC+2SD; PYY)

sensitivity: 15 pg/mL
(MinDC+2SD; Amylin (Total))

sensitivity: 16 pg/mL
(MinDC+2SD; C-Peptide)

sensitivity: 16 pg/mL
(MinDC+2SD; Glucagon)

sensitivity: 160 pg/mL
(MinDC+2SD; Insulin)

sensitivity: 2.4 pg/mL
(MinDC+2SD; GLP-1 (Active))

sensitivity: 2.9 pg/mL
(MinDC+2SD; PP)

sensitivity: 28 pg/mL
(MinDC+2SD; Amylin (Active))

sensitivity: 64 pg/mL
(MinDC+2SD; Leptin)

sensitivity: 7.3 pg/mL
(MinDC+2SD; GLP-1 (Total))

standard curve range: 0.69-500 pg/mL
(TNFα)

standard curve range: 1.4-1,000 pg/mL
(GIP)

standard curve range: 13.7-10,000 pg/mL
(Amylin (Active))

standard curve range: 13.7-10,000 pg/mL
(Amylin (Total))

standard curve range: 13.7-10,000 pg/mL
(Ghrelin (Active))

standard curve range: 13.7-10,000 pg/mL
(Glucagon)

standard curve range: 13.7-10,000 pg/mL
(IL-6)

standard curve range: 13.7-10,000 pg/mL
(MCP-1)

standard curve range: 13.7-10,000 pg/mL
(PYY)

standard curve range: 137-100,000 pg/mL
(Insulin)

standard curve range: 137-100,000 pg/mL
(Leptin)

standard curve range: 2.7-2,000 pg/mL
(GLP-1 (Active))

standard curve range: 2.7-2,000 pg/mL
(GLP-1 (Total))

standard curve range: 2.7-2,000 pg/mL
(PP)

standard curve range: 27.4-20,000 pg/mL
(C-Peptide)

inter-assay cv: <15%
intra-assay cv: <10%
(C-Peptide)

inter-assay cv: <15%
intra-assay cv: <10%
(GIP)

inter-assay cv: <15%
intra-assay cv: <10%
(GLP-1 (Active))

inter-assay cv: <15%
intra-assay cv: <10%
(GLP-1 (Total))

inter-assay cv: <15%
intra-assay cv: <10%
(Ghrelin (Active))

inter-assay cv: <15%
intra-assay cv: <10%
(Glucagon)

inter-assay cv: <15%
intra-assay cv: <10%
(IL-6)

inter-assay cv: <15%
intra-assay cv: <10%
(Insulin)

inter-assay cv: <15%
intra-assay cv: <10%
(Leptin)

inter-assay cv: <15%
intra-assay cv: <10%
(MCP-1)

inter-assay cv: <15%
intra-assay cv: <10%
(PP)

inter-assay cv: <15%
intra-assay cv: <10%
(PYY)

inter-assay cv: <15%
intra-assay cv: <10%
(TNFα)

inter-assay cv: <20%
intra-assay cv: <10%
(Amylin (Active))

inter-assay cv: <20%
intra-assay cv: <10%
(Amylin (Total))

テクニック

multiplexing: suitable

検出方法

fluorometric (Luminex xMAP)

輸送温度

wet ice

詳細

Metabolic syndrome is a cluster of conditions, including increased blood pressure, elevated insulin levels, excess body fat around the waist, and abnormal cholesterol levels. Key features of metabolic syndrome include insulin resistance, glucose intolerance, hypertension, dyslipidemia, and central obesity—all of which are risk factors for atherosclerosis, coronary heart disease, type 2 diabetes, kidney disease, and even premature death. Adults with metabolic syndrome present a low-grade inflammation, whose link with obesity may be a production of pro- and anti-inflammatory factors. Consequently, research done in this area covers multi-faceted fields of cytokines, acute phase proteins, diabetes, and obesity related hormones, as well as other cardiovascular disease biomarkers.

The MILLIPLEX® Human Metabolic Hormone Panel is a 15 analyte, 13-plex kit to be used for the simultaneous quantification of any or all of the following analytes in serum, plasma and cell/tissue culture samples: Amylin (Active) or Amylin (Total), C-Peptide, Ghrelin (Active), GIP, GLP-1 (Active) or GLP-1 (Total), Glucagon, IL-6, Insulin, Leptin, MCP-1, PP, PYY, TNFα. This kit uses a 96-well format, contains a lyophilized standard cocktail, two internal assay quality controls and can measure up to 38 samples in duplicate.

The Luminex® xMAP® platform uses a magnetic bead immunoassay format for ideal speed and sensitivity to quantitate multiple analytes simultaneously, dramatically improving productivity while conserving valuable sample volume.

Panel Type: Metabolism

アプリケーション

  • Analytes: Amylin (Active), Amylin (Total), C-Peptide, Ghrelin (Active), GIP (Total), GLP-1 (Active), GLP-1 (Total), Glucagon, IL-6, Insulin, Leptin, MCP-1 (CCL2), Pancreatic Polypeptide (PP), PYY (Total), TNF-α
  • NOTE: The following analytes cannot be assayed simultaneously: Amylin (Active) & Amylin (Total); GLP-1 (Active) & GLP-1 (Total).
  • Recommended Sample Type: Human serum, plasma, and cell/tissue culture supernatants or lysates
  • Recommended Sample Dilution: 25 μL per well of undiluted serum or plasma; cell/tissue culture samples may be used undiluted or diluted with an appropriate control medium NOTE: The following analytes require the addition of protease inhibitors to serum or plasma samples (see sample collection and storage section in the protocol for details): GLP-1 (DPPIV inhibitor); Amylin (protease inhibitor cocktail); Glucagon (Aprotinin); Ghrelin (Active) (serine protease inhibitor).
  • Assay Run Time: Overnight (16-18 hours) at 2-8°C
  • Research Category: Metabolism
  • Research Subcategory: Metabolic Disorders

特徴および利点

Design your multiplex kit by choosing available analytes within this panel.

関連事項

Replaces: HMHMAG-34K

その他情報

Please contact Technical Service for linearity of dilution.
Please note: Amylin (Active) and Amylin (Total) cannot be plexed together. GLP-1 (Active) and GLP-1 (Total) cannot be plexed together.

法的情報

Luminex is a registered trademark of Luminex Corp
MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany
xMAP is a registered trademark of Luminex Corp

ピクトグラム

Skull and crossbonesEnvironment

シグナルワード

Danger

危険有害性情報

危険有害性の分類

Acute Tox. 3 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Irrit. 2 - Skin Sens. 1

保管分類コード

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects


適用法令

試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。

毒物及び劇物取締法

キットコンポーネントの情報を参照してください

PRTR

キットコンポーネントの情報を参照してください

消防法

キットコンポーネントの情報を参照してください

労働安全衛生法名称等を表示すべき危険物及び有害物

キットコンポーネントの情報を参照してください

労働安全衛生法名称等を通知すべき危険物及び有害物

キットコンポーネントの情報を参照してください

カルタヘナ法

キットコンポーネントの情報を参照してください

Jan Code

キットコンポーネントの情報を参照してください


試験成績書(COA)

製品のロット番号・バッチ番号を入力して、試験成績書(COA) を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする

Patrik Hansson et al.
The Journal of nutrition, 149(3), 422-431 (2019-02-14)
Postprandial lipemia is a risk factor for cardiovascular disease. Dairy products differ in nutrient content and food matrix, and little is known about how different dairy products affect postprandial triglyceride (TG) concentrations. We investigated the effect of meals with similar
Matthieu St-Jean et al.
PloS one, 12(5), e0177110-e0177110 (2017-05-12)
Hepatocyte nuclear factor 1 alpha (HNF1α) defects cause Mature Onset Diabetes of the Young type 3 (MODY3), characterized by defects in beta-cell insulin secretion. However, HNF1α is involved in many other metabolic pathways with relevance for monogenic or polygenic type
Lijuan Sun et al.
The British journal of nutrition, 116(7), 1216-1221 (2016-09-10)
Apart from the well-known action of insulin, the mechanism by which soya and cows' milk improve postprandial glycaemia control was examined. In total, twelve healthy, young, Chinese men were studied on three separate occasions, in random order with isovolumetric (322
Marta Klementova et al.
Nutrients, 11(1) (2019-01-16)
Gastrointestinal hormones are involved in regulation of glucose metabolism and satiety. We tested the acute effect of meal composition on these hormones in three population groups. A randomized crossover design was used to examine the effects of two energy- and
Haitham Abdulla et al.
Endocrinology, diabetes & metabolism, 2(4), e00085-e00085 (2019-10-09)
The effect of substantive doses of essential amino acids (EAA) on incretin and insulin production, and the impact of age upon this effect, is ill-defined. A 15-g oral EAA drink was administered to young (N = 8; 26 ± 4.4 years) and older (N = 8; 69 ± 3.8 years)

関連コンテンツ

MILLIPLEX®マルチプレックス代謝アッセイなどのマルチプレックス・イムノアッセイは、メタボリックシンドローム研究に重要です。糖尿病や肥満など、関連するさまざまな病態の全体像を把握でき、時間とサンプル量を節約できるためです。

質問

1–2/2 質問  
  1. How much protease inhibitor should be added when using only the plasma instead of the entire blood sample?

    1 回答
    1. For most protease inhibitors, such as leupeptin and aprotinin, doubling the concentration typically does not negatively impact the assay. However, with specific inhibitors like the DPPIV inhibitor referenced, higher concentrations can interfere with the assay, which is why additional instructions are provided. Other DPPIV inhibitors, such as Diprotin A, do not interfere at any concentration but are not as effective.

      役に立ちましたか?

  2. Could you please provide information on the epitopes targeted by the antibodies HMHE-1034-2 and HMHE-1034-1, which are used in the MILLIPLEX MAP Human Metabolic Hormone Magnetic Bead Panel - Metabolism Multiplex Assay? Specifically, I would like to know if the anti-GLP-1 antibody would be able to bind to a commercial drug such as semaglutide.

    1 回答
    1. This antidiabetic medication for the treatment of type 2 diabetes and as anti-obesity medication for long-term weight management is known as Semaglutide. It is sold under the brand names Ozempic, Wegovy, and Rybelsus. Semaglutide was developed by Novo Nordisk in 2012. It is a GLP-1 receptor agonist, meaning that it mimics the action of the human incretin glucagon-like peptide-1 (GLP-1), thereby increasing insulin secretion and increasing blood sugar disposal and improving glycemic control.

      役に立ちましたか?

レビュー

評価値なし

アクティブなフィルタ

ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.

製品に関するお問い合わせはこちら(テクニカルサービス)